吗氯贝胺与米帕明治疗抑郁症多中心双盲对照试验  

Moclobemide versus Imipramine, a Multicenter Double-blind Clinical Trial in Chinese Depressive Patients

作　　者：周沫[1] 刘平[1] 舒良[1] 谭春香[1] 老洪尧[2] 郑洪波[2] 顾世芬[3] 范俭雄[3] 宣妙珍 李永远[4] 

机构地区：[1]北京大学精神卫生研究所,100083 [2]广州市精神病医院 [3]南京市脑科医院 [4]苏州广济医院

出　　处：《中国心理卫生杂志》2002年第10期714-716,共3页Chinese Mental Health Journal

摘　　要：目的 :以经典抗抑郁药物米帕明为阳性对照药采用随机双盲双模拟方法对吗氯贝胺和米帕明治疗抑郁症的疗效和安全性进行研究。方法 :共纳入病人 2 0 0例 ,分别口服吗氯贝胺 3 0 0 -60 0mg d或米帕明75 -2 5 0mg d。结果 :两组病人Hamilton抑郁量表 (HAMD)以及Hamilton焦虑量表 (HAMA)总分在治疗结束时均显著下降 (P <0 0 0 1)。两组之间疗效无显著差异 (p >0 0 5 )。治疗结束时HAMD减分率分别为吗氯贝胺组 0 74± 0 2 4,米帕明组 0 74± 0 2 4(P >0 0 5 ) ;有效率吗氯贝胺组 79 4% ,米帕明组 85 4% (P >0 0 5 )。吗氯贝胺组有 10种不良反应发生频率显著低于米帕明组 ,主要是抗胆碱能、中枢神经系统及心血管系统不良反应。吗氯贝胺的疗效指数也显著高于米帕明组。结论Objective:to study the efficacy and safety of moclobemide in comparison with typical antidepressant imipramine Method:200 depressive patients were enrolled for the randomized double blind double-dummy study The dosage of moclobemide was 300-600 mg/d, that of imipramine was 75-250 mg/d Result:at the end of trial, both two groups had lower scores of HAMD and HAMA than before There was no significant difference between the two groups in clinical effect, the effective rate of moclobemide was 79 4%, that of imipramine was 85 4% Moclobemide group had fewer side effects than imipramine group Conclusion:moclobemide is a safe and effective antidepressant

关 键 词：吗氯贝胺 米帕明 抑郁症 临床试验 疗效 安全性 

分 类 号：R749.4[医药卫生—神经病学与精神病学] R971.43[医药卫生—临床医学]